Identification of *Trypanosoma cruzi* Polyamine Transport Inhibitors by Computational Drug Repurposing

Chantal Reigada 1,2, Melisa Sayé 1,2, Otto Phanstiel IV 3, Edward Valera-Vera 1,2, Mariana R. Miranda 1,2 and Claudio A. Pereira 1,2*

1 Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Médicas A. Lanari, Buenos Aires, Argentina, 2 Consejo Nacional de Investigaciones Científicas y Técnicas, Laboratorio de Parasitología Molecular, Instituto de Investigaciones Médicas (IDIM), Universidad de Buenos Aires, Buenos Aires, Argentina, 3 Department of Medical Education, University of Central Florida, Orlando, FL, United States

*Correspondence: Claudio A. Pereira cpereira@ retina.ar

**Open Access**

**Edited by:**
Sunil Dhiman, Defence Research & Development Establishment (DRDE), India

**Reviewed by:**
Juan Diego Maya, University of Chile, Chile
Rubem Figueiredo Sodok, Menna-Barreto, Oswaldo Cruz Foundation (Fiocruz), Brazil

**Specialty section:**
This article was submitted to Infectious Diseases-Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

**Received:** 19 February 2019  
**Accepted:** 24 October 2019  
**Published:** 08 November 2019

**Citation:**  
Reigada C, Sayé M, Phanstiel O IV, Valera-Vera E, Miranda MR and Pereira CA (2019) Identification of *Trypanosoma cruzi* Polyamine Transport Inhibitors by Computational Drug Repurposing. Front. Med. 6:256. doi: 10.3389/fmed.2019.00256

**Keywords:** *Trypanosoma cruzi*, Chagas disease, polyamine transport, drug repositioning, trypanocidal drugs, polyamines

**INTRODUCTION**

*Trypanosoma cruzi* is the causative agent of Chagas disease, a parasitic infection endemic in Latin America. In *T. cruzi* the transport of polyamines is essential because this organism is unable to synthesize these compounds *de novo*. Therefore, the uptake of polyamines from the extracellular medium is critical for survival of the parasite. The anthracene-putrescine conjugate Ant4 was first designed as a polyamine transport probe in cancer cells. Ant4 was also found to inhibit the polyamine transport system and produced a strong trypanocidal effect in *T. cruzi*. Considering that Ant4 is not currently approved by the FDA, in this work we performed computer simulations to find trypanocidal drugs approved for use in humans that have structures and activities similar to Ant4. Through a similarity ligand-based virtual screening using Ant4 as reference molecule, four possible inhibitors of polyamine transport were found. Three of them, promazine, chlorpromazine, and clomipramine, showed to be effective inhibitors of putrescine uptake, and also revealed a high trypanocidal activity against *T. cruzi* amastigotes (IC\(_{50}\) values of 3.8, 1.9, and 2.9 µM, respectively) and trypomastigotes (IC\(_{50}\) values of 3.4, 2.7, and 1.3 µM, respectively) while in epimastigotes the IC\(_{50}\) were significantly higher (34.7, 41.4, and 39.7 µM, respectively). Finally, molecular docking simulations suggest that the interactions between the *T. cruzi* polyamine transporter TcPAT12 and all the identified inhibitors occur in the same region of the protein. However, this location is different from the site occupied by the natural substrates. The value of this effort is that repurposing known drugs in the treatment of other pathologies, especially neglected diseases such as Chagas disease, significantly decreases the time and economic cost of implementation.
need. The available drugs, benznidazole, and nifurtimox, have been used for nearly half a century and can cause severe side effects decreasing the quality of life of the patients. In addition, they are only partially effective in the treatment of the chronic phase of the disease, when most of the patients are diagnosed (3). For example, the recent results of the trial "BENznidazole Evaluation For Interrupting Trypanosomiasis" (BENEFIT) showed that this drug does not produce any improvement on the Chagasic cardiopathy in patients in the chronic phase of the disease, highlighting the necessity for the development of new treatments (4).

Polymamines are aliphatic polycations, which are present in all living organisms. One of the most interesting chemical features of polymamines is the regularly spaced positive charges and their ability to form ionic interactions with other molecules (5). These low-molecular weight compounds are essential for cell survival because they are involved in a wide variety of metabolic processes. In this sense, the most abundant polymamines in nature, putrescine, spermidine, and spermine participate in cell growth and proliferation, signal transduction, gene transcription, and translation processes (6).

In T. cruzi the uptake of polyamines is essential for cell survival because the parasite is not able to synthesize polyamines de novo due to the lack of the enzymes arginine decarboxylase and ornithine decarboxylase. Unlike mammals, T. cruzi only obtains polyamines from the extracellular medium by transport processes (7, 8). The permease called TcPAT12 (also known as TcPOT1) is until now the only functionally validated polyamine transporter in T. cruzi (9, 10). This protein constitutes a promising target for the development of new drugs since: (A) no homologs of the permease have been found in mammals; (B) is responsible for the intracellular availability of essential metabolites, (C) regulates many metabolic pathways and parasite stress responses, (D) mediates the uptake of trypanocidal drugs, (E) is essential to sustain the parasite infection (11), and (F) inhibition of polyamine transport by drugs has a strong trypanocidal effect (12–16).

In cancer cells, high polyamine concentrations are required by every cell stage. Besides polyamine biosynthesis, cancer cells also utilize polyamine importers to augment their intracellular polyamine pools. These transporters can be targeted via the delivery of cytotoxic polyamine conjugates or via drugs which inhibit polyamine uptake (17). The co-administration of polyamine transport and biosynthesis inhibitors was successfully tested in cancer models. For example, the use of benzene derivatives of polyamines in combination with the ornithine decarboxylase inhibitor, difluoromethylornithine (DFMO), produced a cytotoxic effect in Chinese hamster ovary cells (CHO) and L3.6pl human pancreatic cancer cells (18). In addition, similar effects were observed in CHO cells using polymamines conjugated with the cytotoxic anthracene (19).

Prior work with a 9-anthracenylmethyl-putrescine conjugate (Ant4) explored its ability to inhibit polyamine transport and affect cell viability. Ant4 induced cytotoxicity in the HL-60 cell line after only 24 h exposure with an IC50 of 20 µM, and apoptosis was the main mechanism of cell death. Ant4 was shown to inhibit putrescine transport and decreased its intracellular concentration (17). This conjugate was tested not only in mammalian cells, but also in unicellular parasites. For example, in the human malaria parasite Plasmodium falciparum, Ant4 inhibited the proliferation of the intraerythrocytic stage with an IC50 of 0.64 µM (20).

In our previous studies with T. cruzi, Ant4 decreased the putrescine and spermidine transport in epimastigotes, the insect stage of the parasite, with IC50 values of 5.2 and 8.8 µM, respectively. Ant4 also showed a strong trypanocidal effect on trypomastigotes, the bloodstream stage of T. cruzi, with an IC50 of 460 nM, and a selectivity index of about 13. This trypanocidal effect of Ant4 is very promising since it is significantly higher than the observed for benznidazole, the drug currently used to treat Chagas disease. In addition, the combination of both drugs produced a significant increase on the trypanocidal effect compared with individual treatments (14).

One of the strategies applied to identify drugs for neglected diseases is the search for approved compounds used in treating other pathologies. This strategy is known as drug repurposing or drug repositioning. One of the main advantages of this experimental approach is that reduces the time and the economic cost necessary to apply approved drugs in the treatment of other diseases. This is especially relevant in orphan diseases, like Chagas disease, which have only few drug alternatives available. Taking into account the high trypanocidal activity of Ant4, and that this molecule is not approved for use in humans, in this work we identified, using in silico and in vitro strategies, three antipsychotic tricyclic drugs which have similar structure and activity to Ant4.

MATERIALS AND METHODS

Parasites and Cells

Trypanosoma cruzi epimastigotes of the Y strain (5 × 106 cells/mL) were cultured at 28°C in plastic flasks (25 cm2), containing BHT (brain-heart infusion-tryptose, 5 mL) medium supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, 100 µg/mL streptomycin and 20 µg/mL hemin. Vero cells (African green monkey kidney) were cultured in MEM medium supplemented with 10% heat inactivated FCS, 0.15% (w/v) NaHCO3, 100 U/mL penicillin and 100 U/mL streptomycin at 37°C in 5% CO2 atmosphere. Trypomastigotes and amastigotes of the Y strain were obtained from Vero infected cells as previously described (21).

Transport Assays

Aliquots of epimastigote or trypomastigote cells were centrifuged at 8,000 g for 30 s, and washed once with phosphate-buffered saline (PBS). Parasites were resuspended in PBS (0.1 mL) and the assay started by the addition of 0.1 mL of the transport mixture containing [3H]-putrescine or [3H]-spermidine (PerkinElmer’s NEN® Radiochemicals; 0.4 µCi) in the presence of different concentrations of the indicated drug. All the compounds to be tested were dissolved in water. Following incubation during 10 min at 28°C (epimastigotes) or 37°C (trypomastigotes), transport was stopped by adding 1 mL of ice-cold PBS. Cells were centrifuged as indicated above, and washed twice with ice-cold PBS. Cell pellets were resuspended in 0.2 mL of water and...
counted for radioactivity in UltimaGold XR liquid scintillation cocktail (Packard Instrument Co., Meridien CT, USA). Cell viability was assessed by direct microscopic examination. Non-specific uptake and carry over were assayed without incubation or incubated at 4°C (22).

**Trypanocidal Activity Assays**

*T. cruzi* epimastigotes were cultured as described above, in 24-wells plate at a start density of 10^6 cells/mL in BHT medium. Parasites were treated with different concentrations of each drug, and epimastigote proliferation was determined after 24 h. Trypanocidal activity in cell-derived trypomastigotes and amastigotes was performed using 10^6 cells/mL in 96-well plates which were incubated at 37°C for 24 h in the presence of the corresponding drug. Growth was determined by counting in a Neubauer chamber or via viability assays using "Cell Titer 96® Aqueous One Solution Cell Proliferation Assay (MTS)" (Promega, Madison, WI, USA) according to the manufacturer's instructions.

**Cell Viability Assay**

Cytotoxicity against VERO cells was determined by the crystal violet staining assay. The cells (10^4 cells/well) were incubated in 96-well plates with the indicated compound (or diluent only as a negative control) and maintained at 37°C for 24 h. At the end of treatment, cells were fixed for 15 min, and stained with 0.5% crystal violet. After washing with water and drying, the absorbance of stained cells was measured at 570 nm.

**Intracellular Localization of Ant4 and Chlorpromazine by Fluorescence Microscopy**

Epimastigotes (2 × 10^6 cells/ml) were incubated with the corresponding concentrations of each compound for 30 min at 28°C. Afterwards, the samples were settled for 20 min at room temperature onto poly-L-lysine coated coverslips and then fixed for 20 min with 2% paraformaldehyde in PBS. Slides were mounted using 80% glycerol in PBS and cells were observed under an Olympus BX60 fluorescence microscope. Images were recorded with an Olympus XM10 camera.

**Docking Simulations**

The tested molecules as well as the natural ligands of TcPAT12, putrescine, and spermidine, were used to model the mode of interaction with an homology model of the transporter using the molecular docking algorithm in AutoDock 4.5 (26) as described previously (16). For docking simulations, a grid that covers the whole transporter molecule was applied and the program was run using a Lamarckian Genetic Algorithm 100 times, with a population size of 300, and 2.7 × 10^4 as maximum number of generations. The figures of the docking poses where produced using Pymol (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.) and the protein residues important for the interaction with the ligands were colored using Pymol according to the Eisenberg hydrophobicity scale (27).

**Statistics and Data Analysis**

IC_{50} and TIC_{50} values were obtained by non-linear regression of dose-response logistic functions, using GraphPad Prism 6.01 for Windows, and the corresponding R-square was indicated for each curve. All experiments were performed in triplicate and the data are presented as mean ± standard deviation (SD). P-values of the comparisons were calculated using the extra sum of squares F-test.

**RESULTS**

**Similarity Virtual Screening**

Ant4 is an experimental drug for cancer treatment not yet approved for use in humans, which also has a strong trypanocidal action (14). Therefore, the first step to identify an approved drug with similar activity to Ant4 was to perform a similarity-based virtual screening with the final objective of repurposing the resulting drugs as trypanocidal agents. Ant4 was defined as the query molecule to compare with 10,000 chemical structures of the Sweetlead database using the LiSICA software. Applying this strategy, four drugs were chosen for further analysis between the top 10 scored compounds with a Tanimoto coefficient (TC, a structural similarity index) > 0.5, and also considering their availability, price and toxicity. These drugs were promazine (PRM; ZINC ID: 10402; TC = 0.64), chlorpromazine (CHL; ZINC ID: 44027; TC = 0.58), levomepromazine (LVM; ZINC ID: 20246; TC = 0.58), and clomipramine (CLM; ZINC ID: 20248; TC = 0.56). Interestingly, all of them are antipsychotic tricyclic drugs (Figure 1). The LigandScout algorithm was used to identify common chemical features (groups that can participate in chemical interactions with a macromolecule) between Ant4 and the obtained drugs. Feature-based structure alignments were performed and the similarities were calculated as the number of matched feature pairs (MFP; i.e., aromatic ring, hydrophobic area, hydrogen bond donor or acceptor, negative or positive ionizable atom, and metal binding location). For these comparisons, the ten features present in Ant4 were set as references. CHL was the structure that shares more chemical features with Ant4 (5 out of 10); including three hydrophobic interactions, one hydrogen bond donor and one positive ionizable interaction. Alignment results are shown in Supplementary Figures S1, S2.
Inhibition of Polyamine Transport by Ant4 Chemical Analogs

To test the similarity screening predictions, the ability of PRM, CHL, LVM, and CLM to inhibit the polyamine uptake was analyzed. Transport assays were performed in epimastigote cells in the presence of putrescine or spermidine (5 and 15 µM, respectively) and each putative inhibitor in a concentration range of 0–600 µM. Concentrations that inhibit the 50% of the transport activity (TIC50) were calculated. PRM, CHL, and CLM produced an inhibition of putrescine transport with calculated TIC50 values of 51.8 µM, 25.7 µM, and 500 µM, respectively (Figure 2A). However, the spermidine transport was inhibited only by CHL with a calculated TIC50 of 25.7 µM (±1.9) (Figure 2B). LVM did not produce an inhibition of polyamine transport in this concentration range. No alterations in the parasites viability were observed after the transport assays indicating that the inhibitory effect was not due to compounds toxicity.

Trypanocidal Effect of Ant4 Analogs

The trypanocidal activity was evaluated only for those drugs that inhibited polyamine transport activity, namely PRM, CHL, and CLM. Interestingly, all these compounds presented trypanocidal effect against the three stages of T. cruzi. Epimastigotes were treated with each drug in concentrations between 0 and 500 µM and the trypanocidal effect was determined 24 h post-treatment. The calculated concentrations that inhibit the 50% of the parasite proliferation (IC50) were 34.7 µM (±2.3), 41.4 µM (±4.0), and 39.7 µM (±2.8) for PRM, CHL, and CLM, respectively (Figure 3A). Next, the trypanocidal activity of these drugs was also assessed in cell-derived trypomastigotes and amastigotes in concentrations between 0 and 500 µM and IC50 values were calculated 24 h post-treatment. PRM, CHL and CLM showed similar trypanocidal effects on both parasite forms and presented significantly lower IC50 values than those obtained for the epimastigote stage (p < 0.0001 for all drugs); corresponding to 3.4 µM (±0.5), 2.7 µM (±0.2), and 1.3 µM (±0.2) for trypomastigotes cells and 3.8 µM (±0.2), 1.9 µM (±0.1), and 2.9 µM (±0.1) for amastigote parasites (Figures 3B,C). This means that T. cruzi trypomastigotes and intracellular amastigotes, the therapeutically relevant stages present in the mammalian host, are about 10 to 20-fold (depending on the drug) more susceptible than epimastigotes, the insect stage of the parasite. Additionally, the cytotoxicity of drugs was tested using mammalian Vero cells to determine the selectivity index (SI = IC50 on Vero cells/IC50 on trypomastigotes). Cells exposed to PRM, CHL, and CLM for 24 h in a concentration range from 0 to 300 µM showed SI values of 17.9 (IC50 62.8 µM ± 3.6), 9.4 (IC50 26.4 µM ± 0.3), and 38.2 (IC50 53.5 µM ± 2.1), respectively. These results indicate that the drugs are more selective against T. cruzi trypomastigotes than host cells.

Effect of Ant4 Analogs on Polyamine Transport in T. cruzi Trypomastigotes

In order to further test the correlation between the trypanocidal activity of PRM, CHL, and CLM and the polyamine transport, the inhibitory effect of the drugs on putrescine and spermidine uptake in the trypomastigote stage of T. cruzi was also evaluated. PRM, CHL, and CLM were tested at concentrations similar to the TIC50 values calculated on epimastigotes. As occurred with epimastigotes, all the compounds inhibited the putrescine transport in trypanmastigotes. The results showed that 50 µM PRM, 25 µM CHL, and 35 µM CLM produced inhibition of 83% (±2.2), 84.3% (±5.9), and 79.2% (±11.4) respectively. In addition, in this stage of the parasite all drugs also inhibited the spermidine transport. At 25 µM the inhibitions observed were 64.6% (±2.7), 55.7% (±0.7), and 60.2% (±9.5) for PRM, CHL, and CLM, respectively. These results suggest that the compounds evaluated act through a polyamine transport inhibition mechanism in T. cruzi epimastigotes and trypomastigotes.

Binding Properties of Ant4 and Its Chemical Analogs

Using a previously reported homology-modeled structure of the T. cruzi polyamine permease TcPAT12 (16), the ability of Ant4, PRM, CHL, LVM, and CLM to bind the transporter was tested by a computer-assisted simulation method. AutoDock
FIGURE 2 | Effect of promazine, chlorpromazine and clomipramine on polyamine transport in *T. cruzi* epimastigotes. Transport assays were performed incubating 10⁷ epimastigotes with 5 µM [³H]-putrescine (A) or 15 µM [³H]-spermidine (B) in the presence of different concentrations of drugs (PRM, dark gray squares; CLM, light gray diamonds; CHL, black circles) between 0 and 600 µM. The concentrations that inhibit the polyamine transport in a 50% (TIC⁵₀) were calculated by non-linear regression using the GraphPad Prism software (R² PRM = 0.945; R² CLM = 0.962; R² CHL = 0.981 for putrescine, R² CHL = 0.951 for spermidine).

FIGURE 3 | Trypanocidal effect of Ant4 chemical analogs on different stages of the *T. cruzi* life cycle. 10⁶ exponential phase epimastigotes were treated with different concentrations of drugs (PRM, dark gray squares; CLM, light gray diamonds; CHL, black circles) between 0 and 500 µM and incubated for 24 h (A). Culture-derived trypomastigotes (B) or amastigotes (C) (10⁶ cells/mL) were exposed to compounds for 24 h in the concentration range of 0–50 µM (B). Inhibitory concentrations for 50% parasites after 24 h (IC⁵₀) were carried as described in the Materials and Methods section (R² PRM = 0.973; R² CLM = 0.977; R² CHL = 0.923 for epimastigotes; R² PRM = 0.934; R² CLM = 0.966; R² CHL = 0.973 for trypomastigotes; R² PRM = 0.992; R² CLM = 0.995; R² CHL = 0.988 for amastigotes).

TABLE 1 | Predicted binding energies by molecular docking of the tricyclic drugs.

| Compound      | ZINC ID | dG (mean) | dG (lower) |
|---------------|---------|-----------|------------|
| Ant4          | N/A     | −8.38     | −9.90      |
| Clomipramine  | 20248   | −7.35     | −8.29      |
| Chlorpromazine| 44027   | −7.29     | −8.38      |
| Promazine     | 10402   | −6.64     | −7.64      |
| Levomepromazine| 20246  | −6.27     | −7.64      |
| Putrescine*   | 5828633 | −2.42     | −3.31      |
| Spermidine*   | 1532612 | −2.17     | −3.33      |

All tricyclic drugs obtained by similarity searching, in addition to the reference compound Ant4 and the substrates of TcPAT12 (*"), were listed in the table. Columns indicate the compound, the ID according to the ZINC database (http://zinc.docking.org/), the mean (dG mean), and the lower (dG lower) ligand efficiencies of the most populated cluster. Those compounds that produced a significant inhibition of polyamine transport and trypanocidal activity were highlighted (light gray). Ligand efficiency values were calculated using the AutoDock program.

As presented in Table 1, the docking poses with the residues involved in the interaction of each compound with TcPAT12 are schematized in Figure 4. In all the ligands, the aliphatic carbon chain occupies a hydrophobic site formed by residues W241 and A244. In the docking simulations, the putrescine motif in putrescine, spermidine, and Ant4 fell in the same position of the pocket. The polycycle of Ant4 occupied a hydrophobic pocket formed by Y400, I140, T141, Y148, and A244. The ring structures in PRM and its analogs occupy the same hydrophobic pocket as Ant4. Between the promazine derivatives, CHL differs from PRM just in its chlorinated polycycle, and this accounts for the stronger inhibitory effect of CHL. LVM docking pose is very similar to that of CHL, but the methoxy group (that substitutes the Cl) clashes with the protein in a very hydrophilic pocket, which probably explains why LVM was not able to inhibit the transporter experimentally. CLM had a docking pose very similar to all the other compounds, but with the chloride in the opposite side of the pocket. We hypothesize that the additional carbon atoms in the central ring orients the chloride at an angle that makes it unable to occupy the same position as in CHL.
Incorporation of Ant4 and Chlorpromazine

To test whether the tricyclic drugs studied not only block the transport of polyamines but also are incorporated into the cell, the intrinsic fluorescence signal of Ant4 and CHL was used as an analysis tool. When the accumulation of these compounds into cells was visualized by fluorescence microscopy, epimastigotes treated with 50 \( \mu \text{M} \) Ant4 or 25 \( \mu \text{M} \) CHL for 30 min showed that these drugs present very similar pattern of intracellular localization, dispersed through the cytoplasm of the parasites (Figure 5). These results, together with those obtained in transport assays, demonstrate that both Ant4 and CHL are actively transported into the \textit{T. cruzi} cell.

DISCUSSION

Tricyclic neuroleptic drugs, including clomipramine and chlorpromazine, were previously described as therapeutic agents for trypanosomiasis. The most studied mechanism of action was the inhibition of the trypanothione reductase; the enzyme responsible for the synthesis of the antioxidant compound trypanothione, the parasite analog of glutathione (28, 29). However, other properties and multi-target effects were reported, among them are: (a) the inhibition of the enzyme dihydrolipoamide dehydrogenase (30), (b) the interaction with nucleic acids, and (c) the generation of phenothiazines cation radicals. In this work we describe a novel mechanism of action of these drugs in \textit{Trypanosoma cruzi}; the inhibition of the polyamine transporter TcPAT12 in addition to the possible intracellular toxic effects. Using the experimental oncologic drug Ant4 (not approved for use in humans) which has a strong activity on \textit{T. cruzi} we performed a similarity virtual screening and identified three antipsychotic drugs; promazine, chlorpromazine, and clomipramine, which were repositioned as trypanocidal agents. All parasite stages tested for trypanocidal activity were affected by Ant4 and the tricyclic drugs herein reported and an increased sensitivity of the trypomastigote and amastigote stages was observed. It should be noted that psychiatric patients, who receive oral treatments with chlorpromazine or clomipramine within the reference doses, reach plasma concentrations in the range of the calculated IC\textsubscript{50} for both drugs in the stages present in the mammalian host. In consequence these medicines are promising candidates to perform pre-clinical evaluations for the development of new therapeutic alternatives to treat Chagas disease.

The differential trypanocidal effect of polyamine transport inhibitors on \textit{T. cruzi} epimastigote and trypomastigote stages was previously observed by our group (14, 16) and could be explained due to the variability of polyamine concentrations in the niche of
each stage. For example, the epimastigote stage supports a highly variable extracellular media within the intestine of the vector and depends on the feeding status of the insect. In contrast, the trypomastigote stage lives in a medium with scarce fluctuations within the mammalian host. Therefore, it is likely that the trypomastigotes have less efficient compensatory mechanisms to support a decrease in the concentration of polyamines caused by the TcPAT12 inhibitors. The fact that the effect of Ant4 and its analogs is higher in the non-replicative trypomastigote stage also suggests that the main mechanism of toxicity is on the transport of polyamines and not on cell division, where anthracene would also act as a DNA intercalating agent. This sensitivity difference between the stages of the T. cruzi life cycle is important since the trypomastigote is the most sensitive stage and the most relevant from a therapeutic point of view.

Other trypanocidal drugs that inhibit the polyamine transport mediated by TcPAT12 were identified by virtual screening techniques. Isotretinoin, a popular drug used for acne treatment, showed the most stable predicted interaction with TcPAT12 and inhibited the polyamine transport in vitro. Moreover, isotretinoin showed a strong inhibition of trypomastigote burst from infected cells with a calculated IC_{50} of 130 nM and a selectivity index of 920 and is a promising drug for pre-clinical trials (16).

Fluorescence microscopy studies also revealed the uptake and intracellular accumulation of Ant4 and chlorpromazine. Both compounds were internalized by T. cruzi epimastigotes suggesting distinct cellular targets besides polyamine transport. In human cancer cells it has been described that Ant4 anthracene moiety interact and induces DNA damage (17), however, as previously mentioned, no correlation between replication and toxicity was observed. In this sense, further studies are required to identify these targets in the parasite.

Our data suggests that both the putrescine moiety and the large hydrophobic ring of Ant4 contribute to its polyamine transport inhibition activity. From the perspective of designing new TcPAT12 inhibitors, the docking models suggest that these compounds should keep the putrescine motif, while retaining all protonable nitrogen as in the case of Ant4. Moreover, large hydrophobic rings should be present to anchor the drug into the hydrophobic pocket previously described. This work also suggests that halogen substitution on the hydrophobic moiety could provide higher binding affinity for the transporter.

All these results highlight the importance of the polyamine transporter TcPAT12 as a therapeutic target for Chagas disease and drug repositioning as an adequate strategy for drug discovery to treat neglected diseases.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/Supplementary Material.

**AUTHOR CONTRIBUTIONS**

CR and CP conceived and designed the experiments. CR, MS, EV-V, and MM performed the experiments. CR, OP, MS, EV-V, MM, and CP analyzed and interpreted the data. CP and OP contributed reagents, materials, analysis tools, or data. CR, CP, and OP wrote the paper. CR, OP, MS, EV-V, MM, and CP revised the manuscript.

**FUNDING**

This work was supported by Consejo Nacional de Investigaciones Científicas y Técnicas, Agencia Nacional de Promoción Científica y Tecnológica (FONCYT PICT 2015-0539). The research leading to these results has, in part, received funding from UK Research and Innovation via the Global Challenges Research Fund under grant agreement A Global Network for Neglected Tropical Diseases grant number MR/P027989/1. CP and MM are members of the career of scientific investigator; CR, MS, and EV-V are research fellows from CONICET.

**ACKNOWLEDGMENTS**

Special thanks to Lic. Fabio di Girolamo (IDIM-CONICET) for technical support.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2019.00256/full#supplementary-material
REFERENCES

1. Chagas C. Nova Tripanosomiae humana: estudos sobre amorfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de uma nova entidade móbida do homem. Mem Inst Oswaldo Cruz. (1909) 1:159–218. doi: 10.1590/S0070-02761909000200008

2. WHO. Chagas Disease (American Trypanosomiasis). (2019). Available online at: http://www.who.int/chagas/

3. Perez-Molina JA, Molina I. Chagas disease. Lancet. (2018) 391:82–94. doi: 10.1016/S0140-6736(17)31612-4

4. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas' Cardiomyopathy. N Engl J Med. (2015) 373:1295–306. doi: 10.1056/NEJMoa1507574

5. Birkholz LM, Williams M, Niemand J, Louw AI, Persson L, Heby O. Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilities. Biochem J (2011) 438:229–44. doi: 10.1042/BJ20110362

6. Igarashi K, Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochim Biophys Acta. (2000) 1475:59–64. doi: 10.1016/S0005-2728(00)00156-2

7. Carrillo C, Canepa GE, Algranati ID. Molecular and functional characterization of a spermidine transporter (SPAT12) from Trypanosoma cruzi. Biochim Biophys Acta. (2006) 1764:936–40. doi: 10.1016/j.bbamcr.2006.03.215

8. Hasne MP, Coppens I, Soysa R, Ullman B. A high-affinity putrescine-cadaverine transporter from Trypanosoma cruzi. Mol Microbiol. (2010) 76:78–91. doi: 10.1111/j.1365-2958.2010.07081.x

9. Hasne MP, Soysa R, Ullman B. The Trypanosoma cruzi diamine transporter is essential for robust infection of mammalian cells. PLoS ONE. (2016) 11:e0152715. doi: 10.1371/journal.pone.0152715

10. Bouvier LA, Silber AM, Galvao Lopes C, Canepa GE, Miranda MR, Tonelli RR, et al. Post genomic analysis of permeases from the amino acid/auxin family in protozoan parasites. Biochim Biophys Acta. (2004) 1254:547–56. doi: 10.1016/j.bbamcr.2004.07.002

11. Marchese L, Nascimento JF, Damasceno FS, Bringaud F, Michels PAM, Silber AM. The uptake and metabolism of amino acids, and their unique role in the biology of pathogenic trypanosomatids. Pathogens. (2018) 7:36. doi: 10.3390/pathogens7020036

12. Reigada C, Phanstiel O, Miranda MR, Pereira CA. Targeting polyamine transport in Trypanosoma cruzi. Eur J Med Chem. (2018) 147:1–6. doi: 10.1016/j.ejmech.2018.01.083

13. Muth A, Madan M, Archer J, Ocampo N, Rodriguez L, Phanstiel O. Polyamine transport inhibitors: design, synthesis, and combination therapies with difluoromethylornithine. J Med Chem. (2014) 57:348–63. doi: 10.1021/jm401174a

14. Reigada C, Kaur N, Delcros JG. Structure-activity investigations of polyamine-anthracene conjugates and their uptake via the polyamine transporter. Amino Acids. (2007) 33:305–13. doi: 10.1007/s00726-007-0527-y

15. Niemand J, Burger P, Verlinden BK, Reader J, Joubert AM, Kaiser A, et al. Anthracene-polyamine conjugates inhibit in vitro proliferation of intraerythrocytic Plasmodium falciparum parasites. Antimicrob Agents Chemother. (2013) 57:2874–7. doi: 10.1128/AAC.00106-13

16. Andrews NW, Colli W. Adhesion and internalization of Trypanosoma cruzi in mammalian cells. J Protozool. (1982) 29:264–9. doi: 10.1111/j.1550-7408.1982.tb04024.x

17. Pereira CA, Alonso GD, Peveto MC, Flawia MM, Torres NH. L-arginine uptake and L-phosphoarginine synthesis in Trypanosoma cruzi. J Eukaryot Microbiol. (1999) 46:566–70. doi: 10.1111/j.1550-7408.1999.tb05132.x

18. Novick PA, Ortiz OF, Poelman J, Abdulhay AY, Pande VS. SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery. PLoS ONE. (2013) 8:e79568. doi: 10.1371/journal.pone.0079568

19. Lesnik S, Stular T, Brus B, Knez D, Gobec S, Janezic D, et al. LiSiCA: a Software for ligand-based virtual screening and its application for the discovery of butyrylcholinesterase inhibitors. J Chem Inf Model. (2015) 55:1521–8. doi: 10.1021/acs.jcim.5b00136

20. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. (2005) 45:160–9. doi: 10.1021/ci049885e

21. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput. Chem. (2009) 30:2785–91. doi: 10.1002/jcc. 21256

22. Eisenberg D, McLachlan AD. Solvation energy in protein folding and binding. Nature. (1986) 319:199–203. doi: 10.1038/319199a0

23. Kumar S, Ali MR, Bawa S. Mini review on tricyclic compounds as an inhibitor of trypanothione reductase. J Pharm Bioallied Sci. (2014) 6:222–8. doi: 10.4103/0975-7406.142943

24. Strauss M, Rodrigues JHS, Lo Presti MS, Bazan PC, Paglini-Oliva P, et al. In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: a multivariate approach. Exp Parasitol. (2018) 189:19–27. doi: 10.1016/j.exppara.2018.04.016

25. Gutierrez-Correa J, Krauth-Siegel RL, Stoppani AO. Phenothiazine radicals inactivate Trypanosoma cruzi dehydroxylapamide dehydrogenase: enzyme protection by radical scavengers. Free Radic Res. (2003) 37:281–91. doi: 10.1080/1072556021000046622

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.